RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.
Publication
, Journal Article
O'Sullivan, JM; Taylor, J; Gerds, A; Buckley, S; Harrison, CN; Oh, S; List, AF; Howard, K; Dreau, H; Hamblin, A; Mead, AJ
Published in: Leukemia
December 2023
Duke Scholars
Published In
Leukemia
DOI
EISSN
1476-5551
ISSN
0887-6924
Publication Date
December 2023
Volume
37
Issue
12
Start / End Page
2497 / 2501
Related Subject Headings
- Treatment Outcome
- Pyrimidines
- Primary Myelofibrosis
- Nitriles
- Mutation
- Immunology
- Humans
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
O’Sullivan, J. M., Taylor, J., Gerds, A., Buckley, S., Harrison, C. N., Oh, S., … Mead, A. J. (2023). RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. Leukemia, 37(12), 2497–2501. https://doi.org/10.1038/s41375-023-02027-3
O’Sullivan, J. M., J. Taylor, A. Gerds, S. Buckley, C. N. Harrison, S. Oh, A. F. List, et al. “RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.” Leukemia 37, no. 12 (December 2023): 2497–2501. https://doi.org/10.1038/s41375-023-02027-3.
O’Sullivan JM, Taylor J, Gerds A, Buckley S, Harrison CN, Oh S, et al. RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. Leukemia. 2023 Dec;37(12):2497–501.
O’Sullivan, J. M., et al. “RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.” Leukemia, vol. 37, no. 12, Dec. 2023, pp. 2497–501. Epmc, doi:10.1038/s41375-023-02027-3.
O’Sullivan JM, Taylor J, Gerds A, Buckley S, Harrison CN, Oh S, List AF, Howard K, Dreau H, Hamblin A, Mead AJ. RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. Leukemia. 2023 Dec;37(12):2497–2501.
Published In
Leukemia
DOI
EISSN
1476-5551
ISSN
0887-6924
Publication Date
December 2023
Volume
37
Issue
12
Start / End Page
2497 / 2501
Related Subject Headings
- Treatment Outcome
- Pyrimidines
- Primary Myelofibrosis
- Nitriles
- Mutation
- Immunology
- Humans
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology